CLOs on the Move


 
We provide deep scientific knowledge, global understanding and broad expertise to enhance market access and medical communications for improved health outcomes.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Robinson Pharma

Since 1989 Robinson Pharma, Inc. (RPI) has served domestic and international marketers of vitamins and dietary supplements. From its humble beginnings as a contract packager, RPI has grown to become a significant entity in the dietary supplement industry

Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 7,000 employees are united around our mission of improving people`s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries. Five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: People, Quality Health Care Outcomes, Customer Focus, Innovation and Efficiency.

Ostomy

RPS Pharmacy is an affiliate of Millenium Pharmaceuticals and as such, we are committed to quality healthcare with an honest approach that values patient privacy and security. All information provided to us is legally protected under the doctor-patient

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.